NCT00844675View on ClinicalTrials.gov

Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions
Early Gastric AdenocarcinomaAdenocarcinoma, Tubular
Interventions
DRUG

rabeprazole

The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).

DRUG

placebo

The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).

Trial Locations (1)

137-040

Catholic University, Gangnam St. Mary's Hospital, Seoul

All Listed Sponsors
collaborator

Janssen Korea, Ltd., Korea

INDUSTRY

lead

The Catholic University of Korea

OTHER

NCT00844675 - Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection | Biotech Hunter | Biotech Hunter